Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals at least 18 years of age with a diagnosis of PNH \& vaccination against meningococcus.~Exclusion Criteria:~* Abnormal renal or liver function~* History of meningococcal disease~* History of Guillain-Barre syndrome~* Known infection with HIV or Hepatitis B or C~* History of thrombotic events

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TT30 (ALXN1102 Formulation) (Type: EXPERIMENTAL): IV: 0.1, 0.3, and 1.0 mg/kg
- TT30 (ALXN1103 Formulation) (Type: EXPERIMENTAL): IV: 3.0, 6.0, and 10.0 mg/kg~SC: 1.0 and 3.0 mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).